Previous Close | 1.1600 |
Open | 1.1500 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 800 |
Day's Range | 1.1200 - 1.1900 |
52 Week Range | 1.0600 - 8.1400 |
Volume | |
Avg. Volume | 729,053 |
Market Cap | 70.56M |
Beta (5Y Monthly) | 1.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.8080 |
Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.08 |
Viewing insider transactions for Taysha Gene Therapies, Inc.'s ( NASDAQ:TSHA ) over the last year, we see that insiders...
Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy (GAN) ultra-rare disease program - FDA acknowledged MFM32 as an acceptable endpoint with a recommendation to dose additional patients in a double-blind, placebo-controlled design to support Biologics License Application (BLA) submission Organizational and business review by new management with operational, structural and personnel change
State officials have terminated an incentive agreement for a Texas-based biotech that had planned to invest $75 million in a manufacturing facility in Durham. The state's Economic Investment Committee, part of the North Carolina Department of Commerce, voted unanimously Tuesday to terminate a package awarded to Taysha Gene Therapies (Nasdaq: TSHA) in late 2020. The vote was in response to a letter the department received from the company requesting withdrawal from the state's Job Development Investment Grant program.